Company profile
TEVA PHARMACEUTICAL INDUSTRIES LTD
NYSE:TEVABiotechnology: Pharmaceutical Preparations
Drug pipeline (741)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Abacavir Sulfate | approved | — | 0 | — |
| ABIRATERONE ACETATE | approved | — | 26 | approved |
| Acamprosate calcium | approved | — | 0 | — |
| Acarbose | approved | — | 0 | — |
| Acetaminophen | approved | — | 78 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (407)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01260922 | phase1 | completed | 2006-04-01 | 2006-05-01 | Teva Pharmaceuticals USA | 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions. |
| NCT01260948 | phase1 | completed | 2006-04-01 | 2006-05-01 | Teva Pharmaceuticals USA | 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions |
| NCT00835575 | phase1 | completed | 2003-07-01 | 2003-08-01 | Teva Pharmaceuticals USA | 15 mg Mirtazapine Orally Disintegrating Tablets, Fasting |
| NCT00834197 | phase1 | completed | 2003-07-01 | 2003-08-01 | Teva Pharmaceuticals USA | 15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting |
| NCT00835497 | phase1 | completed | 2004-06-01 | 2004-06-01 | Teva Pharmaceuticals USA | 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting |
FDA applications (2560)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| ANDA 021206 | ANDA | PLIVA HRVATSKA DOO | ||||
Loading… | ||||||
| ANDA 040008 | ANDA | WATSON LABORATORIES INC | ||||
Loading… | ||||||
| ANDA 040015 | ANDA | TEVA PARENTERAL MEDICINES INC | ||||
Loading… | ||||||
| ANDA 040023 | ANDA | TEVA PARENTERAL MEDICINES INC | ||||
Loading… | ||||||
| ANDA 040043 | ANDA | WATSON LABORATORIES INC | ||||
Loading… | ||||||